Connect with us

Health

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): Interim results of a randomized, double-blind, controlled, phase 3 trial – MD Linx

MDLinx original journal summary on Vaccines, Internal Medicine from The Lancet

Published

on

Findings demonstrate the high efficacy of BBV152, a whole virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG), in preventing laboratory-confirmed symptomatic COVID-19 disease in adults….

Click here to view the original article.

Continue Reading
Advertisement
Advertisement

Trending